CLINICAL STUDY

Retrospective observational study on the effects and tolerability of flutamide in a large population of patients with various kinds of hirsutism over a 15-year period

Roberto Paradisi and Stefano Venturoli

Department of Obstetrics and Gynecology and Reproductive Biology, S. Orsola Hospital, University Alma Mater Studiorum of Bologna, Massarenti 13, I-40138 Bologna, Italy

(Correspondence should be addressed to R Paradisi; Email: roberto.paradisi@unibo.it)

Abstract

Objective: The aim of the study was to evaluate the long-term effects and tolerability of flutamide (Flu) in hirsute women. To the best of our knowledge, this study represents the largest report, concerning the population studied and the duration of treatment, to evaluate Flu use in hirsutism treatment.

Design, patients and methods: Over a 15-year period spanning from January 1991 to January 2006, a total of 414 premenopausal women with hirsutism of different aetiopathogeneses received yearly reducing doses (250, 125 and 62.5 mg/day) of Flu alone or in combination with oral contraceptives for a period varying from at least 3 to 8 years and more. Clinical and endocrine evaluations were assessed half-yearly and yearly respectively in the first 3 years of the study, and yearly in the following years. Liver function evaluations were assessed quarterly.

Results: Both the groups of patients under Flu therapy showed a marked decrease in hirsutism scores after 12 months compared with basal values. The maximum drug effect was observed after 2 years, and it was maintained during the following years of treatment. Androgens were strongly suppressed during treatment. During the first year of treatment, 6.0% of patients abandoned the study due to hepatic disorders related to the drug. During the following years with the lowest treatment regimen, none of the patients abandoned the study due to hepatic discomfort.

Conclusions: Flu is a satisfactory therapeutic regimen for any form of hirsutism in the long run. Moreover, the use of very low doses of Flu is associated with minimal side-effects and high compliance.

Introduction

Hirsutism is defined as the abnormal growth and male-type distribution of terminal (coarse) hairs on the face and/or the body in women. This is one of the commonest clinical conditions referred to endocrinologists, gynaecologists and dermatologists by about 5–15% of the whole female population of fertile age (1). It is essentially a benign medical disorder, but may represent a first-order psychological problem (1, 2). Hirsutism results from an unbalanced relationship between the androgen level and the sensitivity of the hair follicle to androgen (3). An excessive androgen production by the ovaries and the adrenal glands, or an excessive peripheral androgen activity at the target level is one among the main causes of hirsutism (4, 5).

Today, various satisfactory therapeutic regimens exist for the treatment of hirsutism (6). Among these, flutamide (Flu) is commonly defined as a pure selective anti-androgen with a non-steroidal structure and with no progestogenic, glucocorticoid, androgenic, oestrogenic or anti-gonadotrophic action (7). After oral administration, Flu is broken down rapidly into numerous plasma metabolites, among which, 2-hydroxyflutamide is responsible for the Flu’s anti-androgenic activity (8). The drug acts mainly at the peripheral level blocking competitively the cytoplasmic and nuclear binding of androgens to the receptor (7, 9). Additional effects in reducing androgen synthesis (10) and increasing androgen metabolism to inactive molecules (11) have also been shown.

Since the end of the 1980s up to now, a large series of studies have been published on the effects of Flu on hirsutism in women (6, 12–39). Among these reports, there exists a huge variability on the use of the drug concerning, in particular, the following: i) amount of the doses administered from 62.5 (30) to 750 mg/day (14), ii) duration of the treatment from 28 days (13) to
Materials and methods

Subjects

The study was conducted as a retrospective, observational study, and was approved by our Institutional Review Board. All the procedures followed in the study were in accordance with the Helsinki Declaration of 1975. None of the authors received financial contribution or research support from the makers or distributors of Flu or OC for this study.

Over a 15-year period spanning from January 1991 to January 2006, a total of 414 premenopausal women (mean age ± s.d. 24.0 ± 4.2 years) with mild, moderate or severe hirsutism presented to the Reproductive Medicine Unit of the University of Bologna for treating it participated in the study. All the women were of Caucasian origin. A total of 289 (69.8%) women reported menstrual irregularities, 27 (6.5%) of these were amenorrheic. Each patient underwent a complete clinical and laboratory examination. Mean ± s.d. body mass index was 23.2 ± 3.0 kg/m². Exclusion criteria for the study were tumours of ovarian/adrenal origin, prolactinoma, thyroid disorders, Cushing’s syndrome, diabetes mellitus, obesity (40% over their ideal body weight), and hepatic and thromboembolic disease. Patients who had received hormonal or cosmetic treatment during the 3 and 6 months respectively preceding the start of the study were also excluded. Among all the women studied, an aetiologic diagnosis of hirsutism was made, and the classification is reported in Table 1. Polycystic ovary syndrome (PCOS) was defined and diagnosed in the course of the years according to the National Institutes of Health 1990 consensus criteria, Rotterdam 2003 criteria and, more recently, Androgen Excess Society criteria (40).

Study design and treatment

All patients signed an informed consent, and received Flu in association with or without OC for at least 3 years. In particular, patients received 250 mg/day of Flu (Eulexin, Schering-Plough, Milan, Italy) for the first year as an attack dose, 125 mg/day for the second year as a continuing dose and 62.5 mg/day for the third year as a maintenance dose, and they underwent a six-month clinical examination. After the first 3 years, the patients were allowed to decide whether to continue to undergo the treatment or not with the lower dose (62.5 mg/day) of Flu, according to their personal satisfaction and feelings of well-being and on the basis of negligible side-effects. Patients were assigned to one of the following two treatment groups: the first group (141 patients), which received only Flu, and the second group (273 patients), which received Flu in association with ethinylestradiol (0.030 mg/day) plus gestodene (0.075 mg/day) monophasic OC (Ginoden, Bayer-Schering) for 21 days/month (Flu+OC). The selection was made not by randomization but based on the patients’ choice, independent of the diagnosis made. In the first group (Flu), women who were not sexually active, and adequately instructed to avoid pregnancy at all costs, or women who employed barrier methods or intrauterine contraception to avoid any risk of conception were included. In the second group (Flu+OC), all the women who needed hormonal contraception were included. No significant difference was observed in both mean (±s.d.) age and mean (±s.d.) body mass index in the two groups. Serum human chorionic gonadotrophin (hCG) was negative at the start of the protocol in all the patients. The treatment with Flu with or without OC was initiated on the first day of the menstrual cycle. Before treatment, each patient was studied in the early follicular phase of the menstrual cycle (3–5 days of the cycle) when present, or at random if she was amenorrhoeic. During treatment, each patient of the first group was studied in the basal conditions, whereas each patient of the second group was studied on any of the days of the artificial cycle at random. All the patients agreed not to use waxing, tweezing, shaving, bleaching and electrolysis 30 days before the six-month visit for hirsutism evaluation.

The safety, tolerability, and biochemical, clinical and endocrine evaluations were performed as follows. During the first 3 years of the treatment, side-effect assessment was done continuously, general biochemical and hepatic function evaluation was done quarterly, clinical and hirsutism evaluation was done half-yearly and endocrine evaluation was done yearly. During the follow-up years, patients were requested to undergo at least a quarterly hepatic function evaluation and a yearly clinical, hirsutism and endocrine evaluation.

Table 1 Aetiologic diagnoses of different forms of hirsutism in the women studied.

<table>
<thead>
<tr>
<th>Aetiology</th>
<th>No. of subjects</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hirsute women</td>
<td>414</td>
<td>100</td>
</tr>
<tr>
<td>Polycystic ovary syndrome (PCOS)</td>
<td>279</td>
<td>67.4</td>
</tr>
<tr>
<td>Idiopathic hirsutism (IH)</td>
<td>71</td>
<td>17.2</td>
</tr>
<tr>
<td>Non-classic late-onset adrenal hyperplasia</td>
<td>34</td>
<td>8.2</td>
</tr>
<tr>
<td>Hirsutism of mixed origin (ovarian/adrenal)</td>
<td>12</td>
<td>2.9</td>
</tr>
<tr>
<td>Hyperandrogenic-insulin-resistant syndrome</td>
<td>15</td>
<td>3.6</td>
</tr>
<tr>
<td>Hair-acantosis nigricans syndrome</td>
<td>3</td>
<td>0.7</td>
</tr>
</tbody>
</table>
**Hirsutism evaluation**

Hirsutism was estimated by calculating the hirsutism score according to the Ferriman–Gallwey scale as modified by Hatch et al. (41). Nine body areas (upper lip, cheek and chin, chest, upper back, lower back, upper abdomen, lower abdomen, arm and thigh) that contain androgen-sensitive hairs were graded from 0 (no terminal hair) to 4 (complete hair cover). A score $\geq 8$ was considered as threshold for hirsutism. A score between 8 and 11, between 11 and 18, and $>18$ was considered as mild, moderate and severe hirsutism respectively. In the population studied, the hirsutism score ranged from 8 to 30 in the basal conditions. The clinical evaluation relative to each patient was done by the same investigator, and only two investigators who were highly experienced were allowed to grade hirsutism in the whole study.

Moreover, patients' self-evaluation of the clinical outcome of the treatment was obtained systematically at the end of each year during the treatment. Each patient rated her appreciation as highly satisfied, satisfied or dissatisfied.

**Assays**

Peripheral blood was collected by venipuncture between 0800 and 0900 h. The blood was immediately centrifuged, and serum was stored frozen at $-20^\circ C$ until assay. All serum hormones were measured in duplicate. The techniques used for hormonal measurements are as follows: gonadotrophins (FSH and LH) and prolactin (PRL), using rapid double-antibody kits purchased from Biodata, Rome, Italy; ACTH, using a kit purchased from CIS (Gif-sur-Yvette, France); and cortisol (F), using a kit purchased from the Diagnostic Products Corp. (Los Angeles, CA, USA); and the sex hormone-binding globulin (SHBG) was assessed by plasma extraction with ethyl ether; DHAS was assessed directly in diluted plasma as described previously (42); free testosterone (fT) was assessed by plasma extraction with ethyl ether; DHA and 17-hydroxyprogesterone were assessed by chromatographic separation on Sephadex LH-20 columns; DHA was assessed by plasma extraction with ethyl ether; DHA was assessed directly in diluted plasma as described previously (43); free testosterone (fT) was assessed using the Coat-A-Count procedure of Diagnostic Systems Laboratories (Webster, TX, USA), and the sex hormone-binding globulin (SHBG) was assessed by non-competitive liquid-phase immunoradiometric assay (Farmos Diagnostic, Oulunsalo, Finland). The intra- and interassay variabilities were as follows: 3.7 and 4.2% for FSH; 4.5 and 5.1% for LH; 3.6 and 6.0% for PRL; 4.9 and 9.7% for ACTH; 4.8 and 6.0% for F; 3.9 and 6.1% for $E_1$; 5.1 and 5.9% for $E_2$; 4.5 and 9.3% for testosterone; 8.3 and 13% for DHT; 7 and 10.5% for A; 11.2 and 16.5% for progesterone; 5.0 and 5.2% for 17-hydroxyprogesterone; 6.9 and 8.9% for DHA; 3.6 and 5.6% for DHAS; 3.2 and 3.4% for fT; and 4.6 and 5.6% for SHBG.

**Statistical analysis**

The Shapiro–Wilk test was used to assess the normal distribution of the parameters. Laboratory and clinical data were analyzed using various general linear models addressed to evaluate the effect of group and time upon the variable of interest (hirsutism). Non-parametric test (Mann–Whitney $U$ test) and $\chi^2$ analysis were also applied, when appropriate. A value of $P<0.05$ was accepted as statistically significant. Results are expressed as mean ± 1 s.d.

**Results**

**Clinical results**

Figure 1 shows the mean (± s.d.) percentage changes from baseline in the hirsutism score for 8 years of treatment in both the groups of patients studied. After this period, the clinical data collected from the patients who continued to undergo treatment were too small in numbers to draw any statistical conclusion. No significant difference ($P=NS$) was found during the treatment between the two groups expressed as effect upon the constant term (intercept) of two-way analysis of variance (Fig. 1). Hirsutism improved markedly in almost all the subjects. The mean (± s.d.) basal hirsutism score (17.5 ± 3.6) dropped to 10.5 ± 2.6, 7.9 ± 2.0, 6.1 ± 2.1, 5.6 ± 2.2 and 5.5 ± 2.4 ($P<0.001$).
after 0.5, 1, 1.5, 2 and 3 years of treatment respectively. The mean percentage improvement for hirsutism was ~40, 55, 65, 70 and 70% at 0.5, 1, 1.5, 2 and 3 years of treatment respectively. In the following years of maintaining treatment, the percentage improvement remained almost the same. It is worth mentioning that the mean hirsutism score reached the normal range (< 8) after at least 1 year of treatment, and that the best results were obtained after 2 years of treatment. In particular, mean (±S.D.) basal hirsutism score was 17.8±3.6 and 16.9±3.0 in PCOS and non-PCOS patients respectively. Both scores decreased markedly to 8.1±2.1 and 7.5±2.3 in PCOS patients and to 7.5±1.8, 5.4±1.9 and 5.3±2.1 in patients with idiopathic hirsutism (IH) or other hyperandrogenic states after 1, 2 and 3 years of treatment respectively.

Patients’ self-evaluations of the clinical outcome of the treatment were also consistent with changes in the hirsutism score, and indicated that more than 95% of the subjects were satisfied or highly satisfied in the first 3 years of treatment (Table 2). Almost all the patients continued to express complete satisfaction also in the following years of treatment (data not shown due to the enormous dropout of the subjects).

**Endocrine results**

Table 3 shows the mean (±S.D.) hormonal values in the basal conditions and after 1, 2, 3, 4, 5 and 6 years of treatment in both the groups studied. Serum gonadotrophins (FSH and LH) and PRL levels were significantly reduced and increased respectively in the Flu+OC group, whereas they remained unchanged in the Flu group. Serum ACTH and cortisol levels remained unchanged in both the groups. Inhibitory effects were observed in serum E1, E2, progesterone and 17-hydroxyprogesterone levels in the Flu+OC group, whereas no effect, slight stimulatory effect, slight inhibitory effect and marked inhibitory effect were observed in serum E1, E2, progesterone and 17-hydroxyprogesterone levels respectively in the Flu group. Serum SHBG levels increased clearly in the Flu group, whereas it remained unchanged in the Flu group. Figure 2 reports the androgen levels (testosterone, fT, DHT, A, DHA and DHAS) in the basal conditions and after 1, 2, 3, 4, 5 and 6 years of treatment, and shows a marked decrease of all the androgens induced by Flu in both the groups.

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>Flu</th>
<th>Flu + OC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>First year</td>
<td>Second year</td>
</tr>
<tr>
<td>Total</td>
<td>126</td>
<td>122</td>
</tr>
<tr>
<td>Highly satisfied</td>
<td>96 (76.2)</td>
<td>99 (80.3)</td>
</tr>
<tr>
<td>Satisfied</td>
<td>25 (19.8)</td>
<td>20 (16.4)</td>
</tr>
<tr>
<td>Dissatisfied</td>
<td>5 (4.0)</td>
<td>2 (1.6)</td>
</tr>
</tbody>
</table>

Percentage values reported in parentheses.
### Table 3 Mean (±s.o.) hormonal values in basal conditions and after 1, 2, 3, 4, 5 and 6 years of treatment with flutamide (Flu) and Flu with oral contraceptive (Flu + OC).

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>1 year</th>
<th>2 years</th>
<th>3 years</th>
<th>4 years</th>
<th>5 years</th>
<th>6 years</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Flu</td>
<td>Flu + OC</td>
<td>Flu</td>
<td>Flu + OC</td>
<td>Flu</td>
<td>Flu + OC</td>
<td>Flu</td>
</tr>
<tr>
<td>n</td>
<td>141</td>
<td>273</td>
<td>126</td>
<td>242</td>
<td>122</td>
<td>234</td>
<td>113</td>
</tr>
<tr>
<td>FSH (IU/l)</td>
<td>(4–10)</td>
<td>5.5±1.3</td>
<td>5.4±1.2</td>
<td>3.1±0.8</td>
<td>5.4±1.4</td>
<td>3.0±1.0</td>
<td>5.6±1.2</td>
</tr>
<tr>
<td>LH (IU/l)</td>
<td>(2–10)</td>
<td>6.3±2.4</td>
<td>6.4±2.6</td>
<td>6.1±2.9</td>
<td>5.8±2.6</td>
<td>29±1.2</td>
<td>5.9±2.8</td>
</tr>
<tr>
<td>PRL (ng/ml)</td>
<td>(5–25)</td>
<td>12±5</td>
<td>11±6</td>
<td>12±5</td>
<td>17±9</td>
<td>11±6</td>
<td>18±9</td>
</tr>
<tr>
<td>ACTH (pg/ml)</td>
<td>(5–60)</td>
<td>33±14</td>
<td>35±13</td>
<td>34±14</td>
<td>34±15</td>
<td>33±13</td>
<td>35±14</td>
</tr>
<tr>
<td>F (ng/ml)</td>
<td>(70–240)</td>
<td>204±32</td>
<td>201±30</td>
<td>196±32</td>
<td>200±28</td>
<td>202±33</td>
<td>206±31</td>
</tr>
<tr>
<td>E1 (pg/ml)</td>
<td>(13–48)</td>
<td>48±18</td>
<td>50±16</td>
<td>50±18</td>
<td>31±10</td>
<td>49±17</td>
<td>27±11</td>
</tr>
<tr>
<td>E2 (pg/ml)</td>
<td>(16–53)</td>
<td>48±17</td>
<td>45±13</td>
<td>53±19</td>
<td>23±9</td>
<td>57±20</td>
<td>22±8</td>
</tr>
<tr>
<td>Progesterone (ng/dl)</td>
<td>(10–110)</td>
<td>35±10</td>
<td>37±11</td>
<td>32±9</td>
<td>23±8</td>
<td>32±10</td>
<td>22±7</td>
</tr>
<tr>
<td>17-Hydroxyprogesterone (ng/dl)</td>
<td>(90–125)</td>
<td>136±39</td>
<td>128±35</td>
<td>97±35</td>
<td>81±30</td>
<td>90±31</td>
<td>75±28</td>
</tr>
</tbody>
</table>

Normal hormonal ranges are reported in parentheses. Significance is given for values within the same regimen. † not significant, *P<0.05, **P<0.01, †P<0.001, versus basal.
in particular, stopped to undergo treatment after 12 years. Another fact worth mentioning is that during these years, three undesired pregnancies were observed in the Flu group of patients because of altered function of mechanical contraception or change in sexual habits in the previously not sexually active women. One pregnancy ended in voluntary interruption and the other two pregnancies ended in the birth of normal babies, full-term girl in one case and boy in the other case. In the latter, pregnancy started during the administration of lower dose (62.5 mg/day) of Flu treatment and the boy fortunately presented no signs of feminization.

Discussion

The goal of the present study was to evaluate the efficacy and tolerability of the long-term use of Flu in a large population of hirsute patients. Our study demonstrates that Flu administration causes an evident improvement in hirsutism score with an almost complete and lasting clinical resolution in the majority of patients, independent of the aetiologic diagnosis of hirsutism. In fact, we found no difference in the improvement of hirsutism between PCOS subjects and those with IH or other states of androgen excess, confirming previous data (27). Moreover, this study shows for the first time that very low doses of Flu (62.5 mg/day) are very effective in the long-term treatment of hirsutism. Data reported in the literature on short-term efficacy of Flu are quite homogeneous, and our study provides additional evidence of this efficacy in agreement with ours and other previous studies (6, 12–25, 27–34, 36–38). After 12 months of treatment, hirsutism score dropped to more than half and reached complete normalization, reaching the score of normal, non-hyperandrogenic women (hirsutism score <8). No differences in hirsutism score were observed between patients treated with Flu alone or in combination with OCs, in accordance with other authors who found both therapeutic regimens to be similarly effective and safe in the treatment of hirsutism (20, 33, 39). On long-term use, the efficacy of Flu in reducing hirsutism was further improved in the second year of treatment according to our previous data (32), whereas a stabilization of the results has been observed for the follow-up years up to the eighth year of therapy. These data are largely in agreement with those reported by Castelo-Branco et al. (39), who published only paper on the long-term efficacy of Flu for the treatment of hirsutism. In this recent paper, however, these authors used higher doses of Flu for a shorter time and in a smaller number of patients.
Changes in hair growth have been evaluated by subjective scoring, commonly used in clinical practice as a semi-quantitative measure of the degree of hirsutism. In fact, this method may have some limitations because of its semi-quantitative evaluation; however, the number of patients examined in the study and the strength of statistical significance may eliminate any doubt. Our clinical data were further supported by an objective method of evaluation of the outcomes, such as patients’ self-evaluation of clinical outcome. In the population studied, in fact, more than 95% of women who received Flu felt satisfied or highly satisfied with the therapy at 1, 2 and 3 years. Most of the patients who remained on Flu treatment in the following years also continued to express a wide satisfaction concerning the self-evaluation of clinical outcome and feelings of well-being. Moreover, in a limited sample of subjects, an objective method of hair growth assessment was also employed and codified using an IBAS image analyzer, a special image analysis processor with a sensitivity of 0.001 mm, that evaluated hair diameter, length and growth rate (6, 32). These measurements also correlated well with the clinical scores as reported previously (6, 32).

A remarkable finding of this study is the marked reduction of serum androgens during Flu treatment. The limited utility of the fT assay (due to its low sensitivity) did not impugn the results. The evident decrease in serum androgen levels was in agreement with ours and other previous reports (6, 18, 19, 21, 22, 25, 31, 32, 34, 36–38), and in disagreement with others (16, 23, 27, 29, 30) using different doses of Flu and smaller sizes of the subject sample enrolled. Hence, although Flu is considered a pure anti-androgen, the main action of which is attributed to its peripheral anti-androgenic properties, our data also confirm a direct inhibitory effect on androgen secretion, resulting from a blockade of the steroidogenic enzymes of androgen biosynthesis in both ovarian thecal and adrenal corticoreticular cells, as has been reported already (18, 21, 24). In fact, Flu has been found to inhibit testicular microsomal 17α-hydroxylase and 17–20 desmolase activities in rats (10) and adrenal 17–20 desmolase activity in men (44), suppressing androgen biosynthesis (8), and to accelerate androgen metabolism into less active steroids in castrated men (11). Furthermore, the inhibitory action of Flu on androgen secretion is practically similar in both groups of patients studied. This strengthens the opinion that this inhibitory action is so strong that it minimizes any further beneficial effect on androgen secretion due to the oestroprogestogen supplementation, such as a reduction in the free, biologically active testosterone fraction resulting from the OC-induced increase in SHBG levels. In fact, whilst SHBG levels did not alter during Flu treatment, they increased markedly when Flu was used along with an OC, confirming previous results (16, 20, 37). Concerning gonadotrophins, Flu has no effect on FSH and LH, and also on PRL, confirming the lack of a central anti-gonadotrophic activity, as has been reported already (14, 15). No interference with the ACTH–cortisol axis has been observed during both Flu treatments, confirming ours and other data (18, 25, 32). Flu had no effect on E₁ levels, data not reported in literature, and caused a slight increase in E₂ levels, as has been reported by us already (6). A slight decrease has been observed in progesterone levels during Flu treatment according to Cesur et al (17), but this is in contrast with others (19, 21). The marked decrease observed in 17-hydroxyprogesterone levels supports the inhibitory action of Flu on the 17α-hydroxylase activity, confirming ours and other studies (6, 32, 37). Otherwise, the marked decrease observed in FSH, LH, E₂, E₁, progesterone and 17-hydroxyprogesterone levels in patients treated with Flu and OCs depends on the well-known inhibitory effect exerted by the OCs on hypothalamic–pituitary–gonadal axis.

Flu is toxic to rat hepatocytes as a result of its cytochrome P₄₅₀-mediated biotransformation into electrophilic metabolites (45). Fatal and non-fatal hepatotoxicity associated with the use of Flu has been reported in male prostate cancer (46) and in female hirsutism (47). Considering that flutamide hepatotoxicity appears to be dose dependent (27, 30, 35, 37), the use of very low doses of flutamide (62.5–125 mg/day) seems appropriate to treat hirsutism, so as to almost completely eliminate adverse events caused by the drug. In fact, a tendency to use lower doses of flutamide in the course of time both as monotherapy in the treatment of hirsutism (29, 38) and as polytherapy in association with insulin sensitizers in the treatment of PCOS and related metabolic disorders (35) has been accomplished. In our study, we observed a considerable incidence (25 cases, 6.0%) of liver enzyme increase, almost all during the first year of treatment with 250 mg/day Flu. Castelo-Branco et al. (39) also found a remarkable incidence of hepatic side-effects with this dosage; however, they used the same dose of Flu for the whole, long duration of the treatment. With the use of very low doses of Flu (62.5 mg/day) for a long time, we have observed no case of transaminase variation according to the previous studies conducted with low dosages for short term (30, 35, 38). Therefore, we confirm the observation of Ibanez et al. (35), who declared that the status of ultra-low Flu may gradually evolve from the absence of evidence on toxicity towards the evidence of the absence of hepatotoxicity.

Furthermore, considering that the efficacy of the low-Flu doses (62.5–125 mg) in hirsutism is practically similar to that reported with higher daily doses (375–750 mg) (30, 37), the ideal treatment for hirsutism seems to be, after an adequate period of attack therapy with 250 mg, with doses tending to be slowly reduced in the course of the time according to clinical results, so as to result in long-term therapy using the minimum effective dose and to have prolonged and...
almost definitive outcome. Our observations are in agreement with those of Azziz (1), who underlined that treatments for hirsutism should be continued for at least 2 years to achieve the maximum effect with a subsequent progressive reduction in the dose of antiandrogen employed, and with those of Rittmaster (48), who asserted that these medical therapies will often need to be continued indefinitely.

The cost of the treatment must also be considered before recommending any treatment regimen for hirsutism, and the retail cost of a course of therapy with Flu, in case of very low doses being employed, is not particularly high, notwithstanding the duration of the treatment.

As a whole, this is the first report, in which a very low dose of Flu has been administered for a long time in a large population of patients with any form of hirsutism, and it suggests that the use of this compound for treatment, even though it should be carefully evaluated in each subject, is very ductile and manageable in the short term and more than promising in the long run. Four enormous advantages can be deduced from this: i) a marked effectiveness and, therefore, a constant and satisfactory remission of hirsutism, independently from the diagnosis, ii) an almost complete tolerability, particularly in the liver, during the treatment, iii) a lack or very prolonged postponement of the clinical signs that rebound often after therapy discontinuation (28), iv) reduced charges for the patients. Now, a question arises spontaneously: considering that some patients continue to undergo treatment for 10 years and more, is it possible to extend this ad libitum or at least till menopause, if not otherwise requested (i.e. pregnancy)?

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This work was supported in part by grant from Ministero dell'Istruzione, dell'Università e della Ricerca, Rome, Italy (funds ex-60%).

**Acknowledgements**

The authors thank Eleonora Porcu, MD, for expert help with patient management; Raffaella Fabbrì, BSc, for help with laboratory data; Mohammad Mabrook, MD, for help with manuscript preparation; and Giuseppe Mignemi, MD, for help with table and figure preparations.

**References**


Received 19 March 2010
Accepted 6 April 2010